

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10571991
	Filing Date		2006-03-15
	First Named Inventor	Bernard Barlaam	
	Art Unit	1624	
	Examiner Name	Douglas M. Willis	
	Attorney Docket Number	09963.0008	

U.S.PATENTS

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	2086968	CA	A1	1993-07-21	Zeneca Limited		<input type="checkbox"/>
	2	2004006846	WO	A2	2004-01-22	Ex-Elixis Inc.		<input type="checkbox"/>
	3	2004013091	WO	A2	2004-02-12	Yissum Research Dev. Co. of the Hebrew Univ.		<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10571991
Filing Date	2006-03-15
First Named Inventor	Bernard Barlaam
Art Unit	1624
Examiner Name	Douglas M. Willis
Attorney Docket Number	09963.0008

4	2008076415	WO	A1	2008-06-26	Ex-Elixis Inc.	<input type="checkbox"/>
---	------------	----	----	------------	----------------	--------------------------

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1	Chen, et al., "Elucidating inhibitory models of the inhibitors of epidermal growth factor receptor by docking and 3D-QSAR," Bioorganic and Medicinal Chemistry, (2004) 12, 2409-2417.	<input type="checkbox"/>
	2	Daiichi Sankyo Company, Ltd., et al. v. Matrix Laboratories, Ltd., et al., Appeal from the US District Court for the District of NJ in Case No. 06-CV-03462, 2009-1511, Decided September 9, 2010.	<input type="checkbox"/>
	3	Hickinson, et al., "AZD8931, an Equipotent, Reversible Inhibitor of Signaling by Epidermal Growth Factor Receptor, ERBB2 (HER2), and ERBB3: A Unique Agent for Simultaneous ERBB Receptor Blockade in Cancer," Clinical Cancer Research (2010) 16,1159-1169.	<input type="checkbox"/>
	4	Liu, et al., "Blockage of epidermal growth factor receptor by quinazoline tyrosine kinase inhibitors suppresses growth of human hepatocellular carcinoma," Cancer Letters (2007), 248, 32-40.	<input type="checkbox"/>
	5	Rewcastle, et al., "Tyrosine Kinase Inhibitors. 12. Synthesis and Structure-Activity Relationships for 6-Substituted 4-(Phenylamino)pyrimido[5,4-d]pyrimidines Designed as Inhibitors of the Epidermal Growth Factor Receptor," J. Med. Chem. (1997) 40, 1820-1826.	<input type="checkbox"/>
	6	Thompson, et al., "Tyrosine Kinase Inhibitors. 13. Structure-Activity Relationships for Soluble 7-Substituted 4-[(3-Bromophenyl)amino]pyrido[4,3-d]pyrimidines Designed as Inhibitors of the Tyrosine Kinase Activity of the Epidermal Growth Factor Receptor," J. Med. Chem. (1997) 40, 3915-3925.	<input type="checkbox"/>
	7	Traxler, et al., "4-(Phenylamino) pyrrolopyrimidines: Potent and Selective, ATP Site Directed Inhibitors of the EGF-Receptor Protein Tyrosine Kinase," J. Med. Chem. (1996) 39, 2285-2292.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10571991
Filing Date	2006-03-15
First Named Inventor	Bernard Barlaam
Art Unit	1624
Examiner Name	Douglas M. Willis
Attorney Docket Number	09963.0008

EXAMINER SIGNATURE

Examiner Signature	/Douglas Willis/	Date Considered	03/07/2011
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.